Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Xeris Biopharma Holdings Inc's Business Segments
Xeris Biopharma Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Product
Total Revenue
$ 92
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product0%
- Recorlev0%
- Gvoke47.1%
- Keveyis25.6%
- Royalty, contract and other revenue1.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 173 | - |
| Recorlev | $ 107 | - |
| Gvoke | $ 43 | 47.1% |
2 more segments available
Sign in to unlock the full Xeris Biopharma Holdings Inc dataset.
Revenue by Product & Service Category - FY
- Product99.2%
- Recorlev59.9%
- Gvoke25%
- Keveyis14.3%
- Royalty, contract and other revenue0.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 82 | 99.2% |
| Recorlev | $ 50 | 59.9% |
| Gvoke | $ 21 | 25% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Xeris Biopharma Holdings Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- Recorlev0%
- Gvoke47.1%
- Keveyis25.6%
- Royalty, contract and other revenue1.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 173 | - |
| Recorlev | $ 107 | - |
| Gvoke | $ 43 | 47.1% |
2 more segments available
Sign in to unlock the full Xeris Biopharma Holdings Inc dataset.
Description of Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc. is a US-based pharmaceutical company focused on developing and commercializing innovative, differentiated therapeutics for people with serious and life-threatening conditions. Xeris was founded in 2005 and is headquartered in Chicago, Illinois.
The company's primary focus is on the development of injectable and infusible drug formulations that are stable at room temperature, making them more convenient and accessible for patients. Their lead product, Gvoke HypoPen, is a ready-to-use, premixed, pre-measured glucagon emergency kit that treats severe hypoglycemia in adults and children with diabetes. The kit received FDA approval in August 2019 and is available for purchase in the US.
Xeris has also developed several other products under development, including a ready-to-use glucagon rescue pen for hypoglycemia associated with insulin therapy, a stable liquid glucagon for use in a healthcare setting, and an epilepsy treatment using Xeris' proprietary formulation technology.
In addition to its internal development programs, Xeris has entered into strategic partnerships and collaborations to further advance their technology and product pipeline. These partnerships include collaborations with Zealand Pharma, Intarcia Therapeutics, and Vizient, among others.
Xeris is led by a highly experienced executive team and has raised over $100 million in funding, including a successful initial public offering in 2018. The company has also been recognized for its innovation and leadership in the industry, receiving awards such as the Red Herring Top 100 North America and being named as one of FierceBiotech's Fierce 15 in 2018.
Overall, Xeris Biopharma Holdings Inc. is a rapidly growing and innovative pharmaceutical company with a strong focus on developing therapeutics that improve patient outcomes and make treatments more accessible and convenient for patients.
The company's primary focus is on the development of injectable and infusible drug formulations that are stable at room temperature, making them more convenient and accessible for patients. Their lead product, Gvoke HypoPen, is a ready-to-use, premixed, pre-measured glucagon emergency kit that treats severe hypoglycemia in adults and children with diabetes. The kit received FDA approval in August 2019 and is available for purchase in the US.
Xeris has also developed several other products under development, including a ready-to-use glucagon rescue pen for hypoglycemia associated with insulin therapy, a stable liquid glucagon for use in a healthcare setting, and an epilepsy treatment using Xeris' proprietary formulation technology.
In addition to its internal development programs, Xeris has entered into strategic partnerships and collaborations to further advance their technology and product pipeline. These partnerships include collaborations with Zealand Pharma, Intarcia Therapeutics, and Vizient, among others.
Xeris is led by a highly experienced executive team and has raised over $100 million in funding, including a successful initial public offering in 2018. The company has also been recognized for its innovation and leadership in the industry, receiving awards such as the Red Herring Top 100 North America and being named as one of FierceBiotech's Fierce 15 in 2018.
Overall, Xeris Biopharma Holdings Inc. is a rapidly growing and innovative pharmaceutical company with a strong focus on developing therapeutics that improve patient outcomes and make treatments more accessible and convenient for patients.
Xeris Biopharma Holdings Inc. is a specialty pharmaceutical company dedicated to addressing unmet medical needs through innovative drug delivery solutions. The company focuses on developing non-aqueous, ready-to-use formulations that significantly enhance the ease of administration for various medications, ultimately leading to improved patient outcomes and reduced healthcare costs.
Segments
Xeris operates within a singular business segment centered on the development, commercialization, and manufacture of medical devices and injectable formulations. This segment emphasizes the creation of user-friendly products designed to simplify the administration of complex therapies, enhancing the patients experience and ensuring optimal treatment outcomes.
Products
1. Gvoke:
- Description: Gvoke is an FDA-approved glucagon injection specifically formulated for the rapid treatment of severe hypoglycemia in individuals with diabetes. Unlike traditional glucagon kits that require reconstitution and preparation, Gvoke comes in a ready-to-use format.
- Patient Accessibility: It is designed for use by the patients themselves, caregivers, and family members, which empowers non-medical personnel to effectively respond to hypoglycemic events.
- Formulation Advantage: The non-aqueous formulation not only simplifies the process but also ensures stability and efficacy of the drug, addressing critical situations swiftly.
2. Ogluo:
- Description: Ogluo is an investigational drug that represents a new approach to managing hypoglycemia for patients with diabetes, specifically tailored for mild to moderate hypoglycemic episodes.
- Product Differentiation: Ogluo differs from traditional glucagon therapies, aiming to offer greater convenience and ease of administration. Its design targets those who may find traditional glucagon kits complex or intimidating, thus potentially increasing adherence and effective use among patients.
- Development Status: Currently in the investigational phase, Ogluo aims to provide a simplified solution with streamlined administration, possibly altering the landscape of mild to moderate hypoglycemia management.
3. Pramlintide-Insulin Combination:
- Description: This investigational product integrates pramlintide, a synthetic analog of amylin, with insulin to deliver a comprehensive treatment strategy for patients with Type 1 and Type 2 diabetes.
- Mechanism of Action: This combination is intended to enhance glycemic control by mimicking the natural effects of amylin, thereby working synergistically with insulin to reduce postprandial blood glucose excursions.
- Target Population: Targeted towards diabetic patients who have difficulties achieving adequate glycemic control with insulin therapy alone, this product represents a forward-thinking approach to diabetes management.
Services
Beyond its innovative product offerings, Xeris Biopharma is committed to providing several essential services aimed at supporting healthcare providers, patients, and payers:
- Patient Assistance Programs: Xeris Biopharma facilitates access to its therapies through patient assistance initiatives, aimed at helping those who may be financially burdened throughout their treatment journey. This can include copay assistance and free medication programs to ensure patients can obtain necessary medications without excessive out-of-pocket costs.
- Reimbursement Support: Recognizing the complexities of healthcare reimbursement, Xeris provides guidance and support to healthcare providers and patients on insurance coverage and reimbursement processes for its products. This service seeks to minimize barriers to access, ensuring that prescribed therapies can be utilized effectively.
- Research and Development Commitment: The company is steadfast in its commitment to continuous research and development, striving to uncover new potential applications for its non-aqueous formulations. With ongoing efforts in various therapeutic areas, Xeris aims to expand its product line and improve treatment accessibility for more patient populations.
In summary, Xeris Biopharma Holdings Inc. focuses on innovative drug delivery technologies, primarily through their ready-to-use formulations, and supports their offerings with dedicated services that enhance patient access and outcomes. Their commitment to research and innovation is reflected in their pipeline of investigational products set to address key challenges in the management of diabetes and related conditions.
Segments
Xeris operates within a singular business segment centered on the development, commercialization, and manufacture of medical devices and injectable formulations. This segment emphasizes the creation of user-friendly products designed to simplify the administration of complex therapies, enhancing the patients experience and ensuring optimal treatment outcomes.
Products
1. Gvoke:
- Description: Gvoke is an FDA-approved glucagon injection specifically formulated for the rapid treatment of severe hypoglycemia in individuals with diabetes. Unlike traditional glucagon kits that require reconstitution and preparation, Gvoke comes in a ready-to-use format.
- Patient Accessibility: It is designed for use by the patients themselves, caregivers, and family members, which empowers non-medical personnel to effectively respond to hypoglycemic events.
- Formulation Advantage: The non-aqueous formulation not only simplifies the process but also ensures stability and efficacy of the drug, addressing critical situations swiftly.
2. Ogluo:
- Description: Ogluo is an investigational drug that represents a new approach to managing hypoglycemia for patients with diabetes, specifically tailored for mild to moderate hypoglycemic episodes.
- Product Differentiation: Ogluo differs from traditional glucagon therapies, aiming to offer greater convenience and ease of administration. Its design targets those who may find traditional glucagon kits complex or intimidating, thus potentially increasing adherence and effective use among patients.
- Development Status: Currently in the investigational phase, Ogluo aims to provide a simplified solution with streamlined administration, possibly altering the landscape of mild to moderate hypoglycemia management.
3. Pramlintide-Insulin Combination:
- Description: This investigational product integrates pramlintide, a synthetic analog of amylin, with insulin to deliver a comprehensive treatment strategy for patients with Type 1 and Type 2 diabetes.
- Mechanism of Action: This combination is intended to enhance glycemic control by mimicking the natural effects of amylin, thereby working synergistically with insulin to reduce postprandial blood glucose excursions.
- Target Population: Targeted towards diabetic patients who have difficulties achieving adequate glycemic control with insulin therapy alone, this product represents a forward-thinking approach to diabetes management.
Services
Beyond its innovative product offerings, Xeris Biopharma is committed to providing several essential services aimed at supporting healthcare providers, patients, and payers:
- Patient Assistance Programs: Xeris Biopharma facilitates access to its therapies through patient assistance initiatives, aimed at helping those who may be financially burdened throughout their treatment journey. This can include copay assistance and free medication programs to ensure patients can obtain necessary medications without excessive out-of-pocket costs.
- Reimbursement Support: Recognizing the complexities of healthcare reimbursement, Xeris provides guidance and support to healthcare providers and patients on insurance coverage and reimbursement processes for its products. This service seeks to minimize barriers to access, ensuring that prescribed therapies can be utilized effectively.
- Research and Development Commitment: The company is steadfast in its commitment to continuous research and development, striving to uncover new potential applications for its non-aqueous formulations. With ongoing efforts in various therapeutic areas, Xeris aims to expand its product line and improve treatment accessibility for more patient populations.
In summary, Xeris Biopharma Holdings Inc. focuses on innovative drug delivery technologies, primarily through their ready-to-use formulations, and supports their offerings with dedicated services that enhance patient access and outcomes. Their commitment to research and innovation is reflected in their pipeline of investigational products set to address key challenges in the management of diabetes and related conditions.